查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2016896

移植诊断市场：按诊断应用、技术、器官类型和最终用户分類的全球市场预测 – 2026-2032 年

Transplant Diagnostics Market by Diagnostic Application, Technology, Organ Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，移植诊断市值将达到 67.8 亿美元，到 2026 年将成长到 72 亿美元，到 2032 年将达到 109.2 亿美元，复合年增长率为 7.03%。

主要市场统计数据
基准年 2025 67.8亿美元
预计年份：2026年 72亿美元
预测年份 2032 109.2亿美元
复合年增长率 (%) 7.03%

全面介绍移植诊断，说明分子层级创新、临床工作流程和指导治疗途径的监管要求之间的交会点。

移植诊断处于免疫学、分子生物学和临床工作流程优化的关键交叉点，快速可靠的诊断是患者预后和计画永续性的基础。分子检测、次世代定序和数位PCR的最新进展扩展了临床医生和检查室管理人员可用的诊断工具，从而能够更精准地进行捐赠者-受体匹配、更早发现移植失败并加强病原体监测。这些技术进步与强调快速週转、自动化数据整合和可扩展检查室模式的营运趋势相辅相成，这些趋势支持高通量检测，同时又不影响分析的严谨性。

新的分子诊断平台、数位整合和协作证据产生如何改变移植诊断的临床实践和应用路径？

随着新兴技术、数据驱动的医疗模式和不断演进的临床方案的整合并重新定义标准实践，移植诊断的格局正在改变。首先，分子诊断正从单一检测转向多项检测和基于定序的方法，从而提供更详细的免疫遗传学和病原体谱。这种转变正在改变移植团队选择捐赠者、免疫抑制管理和移植后追踪的方式，因为临床医生现在可以观察生物标记后续观察时间推移的演变，而不是孤立的简介。

评估近期美国关税措施对移植诊断的采购、製造和临床工作流程的营运和供应链影响。

美国2025年实施的关税政策进一步加剧了依赖全球供应链的製造商、检查室和临床计画的复杂性。依赖进口的组件，例如专用试剂、仪器零件和定序耗材，正面临采购成本上升和采购计画中断的双重困境。因此，检查室管理人员必须重新评估与供应商的关係，以实现供应商网路多元化，并在某些情况下优先考虑安全库存，以维持侦测服务的连续性。

深入的細項分析揭示了诊断应用、技术模式、器官特定需求和最终用户结构如何影响采用和投资重点。

对市场区隔的深入理解能够提供切实可行的洞见，帮助我们了解临床需求和技术应用趋势的差异。从诊断角度来看，供受者配对、移植监测、 HLA型检测和传染病筛检各自占据不同的临床路径，具有不同的分析重点。在HLA型检测中，分辨率需求存在双重性。高解析度检测能够在复杂病例中实现精确的等位基因水平配型，而低解析度方法则继续满足常规相容性筛检的需求。传染病筛检涵盖细菌、真菌和病毒领域，病毒监测本身需要针对巨细胞病毒、 EB病毒、肝炎病毒和HIV等病原体进行标靶检测，每种病原体都对检查室的灵敏度和反应时间提出了特定的要求。

此区域分析详细阐述了临床能力、监管多样性和供应链趋势如何影响全球医疗保健市场采用模式的差异。

了解区域趋势对于理解临床实践、法规结构和报销政策如何影响移植医学中诊断技术的应用至关重要。在美洲，临床网路和中心检查室通常优先考虑快速分子检测和精简的供应链，而大型移植中心则作为早期采用者和标桿，影响全国的医疗实践。在欧洲、中东和非洲，不同的法规环境、报销机制和检查室基础设施导致了广泛的技术应用率频谱，无论是先进的医疗实践还是资源有限的环境，都优先考虑经济高效且可靠的检测方法。在亚太地区，对检测能力的快速投资，加上临床病例的增加以及对本土生产的重视，正在加速定序和基于PCR的诊断技术的应用，尤其是在都市区三级医疗机构中。

以专业创新者、平台供应商和资讯解决方案之间的互动为重点的竞争格局分析。

移植诊断领域的竞争动态体现了利基创新企业与大规模平台供应商之间的平衡，后者提供涵盖检测、仪器和资讯学的一体化解决方案。利基企业通常在检测创新方面发挥主导作用，提供高解析度HLA型检测、标靶病毒监测以及针对特定未满足临床需求的新型生物标记方法。相较之下，大型企业则利用规模经济，投资于检查室自动化、全球分销网络和监管合规项目，促进更广泛的市场渗透。检测开发人员、仪器製造商和临床网路之间的伙伴关係与策略联盟日益普遍，为检验临床效用和透过现有管道加速推广提供了途径。

为诊断开发人员、检查室和临床领导者提供实用建议，以使证据产生、互通性和强大的供应策略与推广目标保持一致。

行业领导者应优先考虑证据生成、互通性和供应链韧性，以将技术潜力转化为常规临床实践。首先，新诊断方法的申办者必须投资于严格的临床检验试验和真实世界证据（RWE）项目，以证明其在具有代表性的移植患者群体和各种医疗环境中的临床效用。这种方法有助于制定合理的使用指南，同时增强临床医生的信心并促进支付方的参与。其次，供应商和实验室在设计时应考虑互通性，采用标准化的报告格式、电子健康记录应用程式介面（API）以及与实验室资讯系统的整合。这可以降低采用门槛，并实现跨医院网路的可扩展部署。

透明严谨的调查方法结合了临床文献、监管指南和该领域医疗保健专业人员的见解，以支持实证结论。

本执行摘要的研究整合了同行评审文献、监管指南、官方临床指南以及近期行业资讯披露，以确保提供平衡且基于证据的观点。主要资料来源包括临床检验研究、检测性能报告以及说明检测方法和分析特性的技术白皮书。研究人员仔细审查了监管和指导文件，以了解检验、报告和检查室品质保证方面不断变化的要求。此外，还纳入了实验室主任、移植临床医生和供应链经理的定性回馈，以反映有关实施、週转和采购方面的实际考虑因素。

该摘要强调了技术成熟度、营运韧性和协作证据产生将如何决定移植诊断的临床影响和传播轨迹。

先进的分子技术、检查室自动化程度的提升以及临床期望的不断提高，共同使得移植诊断成为改善移植效果和增强病患安全的关键要素。从供体选择、 HLA型检测到感染疾病监测和移植监测，高解析度诊断和整合资料工作流程在整个临床流程中的应用，正在重塑医疗决策。同时，贸易政策的变化和区域产能差异等外部压力凸显了建构具有韧性的供应链、在地检验和弹性部署策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按诊断应用分類的移植诊断市场

  • 供者相容性评估
  • 移植监测
  • HLA型检测
    • 高解析度
    • 低解析度
  • 传染病筛检
    • 细菌筛检
    • 真菌筛检
    • 病毒筛检
      • 巨细胞病毒
      • EB病毒
      • 肝炎病毒
      • HIV

第九章 移植诊断市场：依技术划分

  • 酵素法
  • 流式细胞技术
  • PCR
    • 数位PCR
    • QPCR
  • 定序
    • 新一代
    • 桑格

第十章 按器官分類的移植诊断市场

  • 心
  • 肾
  • 肝
  • 肺
  • 胰臟

第十一章 移植诊断市场：依最终使用者划分

  • 诊断检查室
  • 医院
    • 私立医院
    • 公立医院
  • 研究机构
  • 移植中心

第十二章 移植诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 移植诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 移植诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国移植诊断市场

第十六章：中国移植诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • altona Diagnostics GmbH
  • Arquer Diagnostics Ltd.
  • BAG Group
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogenuix Medsystems Pvt. Ltd
  • BioMerieux SA
  • Bruker Corporation
  • Caredx Inc.
  • CareDx, Inc.
  • CLONIT srl
  • Diagnostica Longwood SL
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Genome Diagnostics BV
  • Hologic, Inc.
  • Illumina, Inc
  • Immucor, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Novartis AG
  • PathoNostics BV
  • QIAGEN, NV
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TransMedics, Inc.
  • Zimmer Biomet Group
Product Code: MRR-031685195790

The Transplant Diagnostics Market was valued at USD 6.78 billion in 2025 and is projected to grow to USD 7.20 billion in 2026, with a CAGR of 7.03%, reaching USD 10.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.78 billion
Estimated Year [2026] USD 7.20 billion
Forecast Year [2032] USD 10.92 billion
CAGR (%) 7.03%

A comprehensive introduction to transplant diagnostics that explains the convergence of molecular innovation, clinical workflows, and regulatory imperatives guiding care pathways

Transplant diagnostics occupies a pivotal intersection of immunology, molecular biology, and clinical workflow optimization, where rapid and reliable diagnostics underpin patient outcomes and program sustainability. Recent advances in molecular assays, next-generation sequencing, and digital PCR have expanded the diagnostic toolkit available to clinicians and laboratory directors, enabling more precise donor-recipient matching, earlier detection of graft injury, and refined pathogen surveillance. These technological improvements are complemented by operational trends that emphasize faster turnaround, automated data integration, and scalable laboratory models that can support high-throughput testing without sacrificing analytical rigor.

Consequently, stakeholders from transplant centers to diagnostic laboratories are recalibrating clinical pathways and procurement processes to capture the clinical value of advanced diagnostics while managing cost and complexity. In parallel, regulatory attention on assay validation, data integrity, and interoperability is intensifying, which drives a greater need for standardized workflows and evidence generation. As a result, leaders must weigh the clinical benefits of novel assays against implementation realities, aligning stakeholders across clinical, laboratory, and administrative functions to ensure that diagnostic innovations translate into measurable improvements in graft survival and patient safety.

How emerging molecular platforms, digital integration, and collaborative evidence generation are reshaping clinical practice and adoption pathways in transplant diagnostics

The landscape of transplant diagnostics is shifting as emerging technologies, data-centric care models, and evolving clinical protocols converge to redefine standard practice. First, molecular diagnostics are moving from single-analyte tests toward multiplexed and sequencing-based approaches that deliver richer immunogenetic and pathogen profiles. This transition is changing how transplant teams approach donor selection, immunosuppression management, and post-transplant surveillance, because clinicians now have access to longitudinal biomarker trajectories rather than isolated snapshots.

Second, laboratory automation and digital integration are reducing manual variability and shortening test turnaround times, which supports more dynamic clinical decision-making. As a result, transplant programs are able to adopt more proactive monitoring regimens that detect graft injury earlier and enable timely therapeutic adjustments. Third, the regulatory and reimbursement environment is evolving to address clinical utility and evidence thresholds for novel diagnostics, prompting manufacturers and health systems to invest in real-world evidence studies and payer engagement. Finally, partnerships between diagnostics firms, clinical centers, and data platforms are accelerating the development of companion diagnostics and standardized reporting frameworks, which together lower barriers to adoption and create pathways for scalable implementation across diverse healthcare settings.

Evaluating the operational and supply chain repercussions of recent United States tariff measures on transplant diagnostics procurement, manufacturing, and clinical workflows

In 2025, tariff policies introduced in the United States have introduced an additional layer of complexity for manufacturers, laboratories, and clinical programs that rely on global supply chains. Import-dependent components, including specialized reagents, instrumentation parts, and sequencing consumables, face increased procurement costs and disrupted sourcing timelines. As an immediate consequence, laboratory managers have had to reassess vendor relationships, diversify supplier networks, and in some cases prioritize inventory safety stock to preserve continuity of testing services.

At the same time, manufacturers are responding by rationalizing regional manufacturing footprints and accelerating localization efforts to mitigate exposure to tariff-related volatility. These adjustments often require substantial capital investment and longer lead times to realize cost benefits. Meanwhile, clinical programs that operate under fixed reimbursement regimes feel pressure on operating margins, prompting tighter prioritization of test utilization and greater scrutiny over cost-effectiveness. In response, many stakeholders are adopting strategic sourcing strategies and reengineering workflows to optimize batch processing and consolidate testing where clinically appropriate. Over the medium term, supply chain resilience, supplier diversification, and contractual flexibility will become essential capabilities for organizations seeking to maintain service continuity and manage the financial impacts of trade policy shifts.

Insightful segmentation analysis revealing how diagnostic application, technological modality, organ-specific needs, and end-user structures shape adoption and investment priorities

A granular understanding of market segments provides actionable insight into where clinical demand and technology adoption are diverging. When viewed through diagnostic application lenses, donor and recipient matching, graft monitoring, HLA typing, and infectious disease screening occupy distinct clinical pathways with different analytical priorities. HLA typing presents a duality of resolution needs where high-resolution assays enable precise allele-level matching for complex cases while low-resolution approaches continue to satisfy routine compatibility screening. Infectious disease screening spans bacterial, fungal, and viral domains, with viral surveillance itself requiring targeted assays for pathogens such as cytomegalovirus, Epstein-Barr virus, hepatitis viruses, and HIV, each of which imposes specific sensitivity and turnaround constraints on laboratories.

Technology segmentation further clarifies adoption trajectories: enzymatic assays and flow cytometry maintain foundational roles in many diagnostic workflows, while PCR modalities, including quantitative PCR and digital PCR, deliver high-sensitivity quantitation useful for viral load monitoring and minimal residual disease detection. Sequencing technologies, both next-generation and Sanger, are increasingly applied for HLA allele characterization and complex pathogen genotyping, yielding higher-resolution data that supports personalized immunosuppression strategies. Organ-type segmentation highlights differentiated clinical requirements across heart, kidney, liver, lung, and pancreas transplantation, where graft-specific biomarkers, monitoring frequency, and risk tolerances drive distinct testing patterns. Finally, end-user segmentation reveals the operational perspectives of diagnostic laboratories, hospitals, research institutes, and transplant centers; within hospitals, the distinction between private and public institutions affects procurement models, budgetary constraints, and adoption timelines. Together, these intersecting segmentations elucidate where investments in assay development, laboratory automation, and clinical validation will produce the greatest clinical and operational impact.

Regional intelligence detailing how clinical capacity, regulatory diversity, and supply chain dynamics drive differentiated adoption patterns across global healthcare markets

Regional dynamics are critical to understanding how clinical practice, regulatory frameworks, and reimbursement policies influence diagnostic adoption in transplant care. In the Americas, clinical networks and centralized laboratories often prioritize rapid molecular assays and streamlined supply channels, with major transplant centers serving as early adopters and reference hubs that influence national practices. In Europe, Middle East & Africa, heterogeneity in regulatory environments, reimbursement mechanisms, and laboratory infrastructure produces a wide spectrum of adoption rates, where pockets of advanced practice coexist with resource-constrained settings that emphasize cost-effective, robust assays. In the Asia-Pacific region, rapid investments in laboratory capacity, combined with growing clinical volumes and a focus on domestic manufacturing, are driving accelerated uptake of sequencing and PCR-based diagnostics, especially in urban tertiary centers.

Across these regions, interoperability, harmonized standards, and cross-border data sharing remain pivotal for multicenter studies and longitudinal surveillance programs. Consequently, regional strategies must reconcile global best practices with local regulatory realities and supply chain considerations, enabling scalable implementations that respect differences in clinical workflows and payer systems. Strategic regional partnerships and localized validation studies are effective mechanisms to bridge capability gaps and to translate innovative diagnostics into routine practice across diverse healthcare ecosystems.

Competitive landscape analysis emphasizing the interplay of specialized innovators, platform providers, and informatics solutions that determine market leadership and clinical adoption

Competitive dynamics in transplant diagnostics reflect a balance between specialized innovators and larger platform providers that offer integrated solutions spanning assays, instrumentation, and informatics. Niche firms often lead in assay innovation, delivering high-resolution HLA typing, targeted viral surveillance panels, and novel biomarker approaches that address specific unmet clinical needs. Larger entities, by contrast, leverage scale to invest in laboratory automation, global distribution networks, and regulatory programs that facilitate broader market penetration. Partnerships and strategic alliances between assay developers, instrument manufacturers, and clinical networks are increasingly common, providing a pathway to validate clinical utility and to accelerate adoption through established channels.

In parallel, software and informatics players are becoming critical competitive differentiators by enabling standardized reporting, longitudinal data visualization, and integration with electronic health records. These capabilities enhance clinical utility by converting raw assay outputs into actionable insights for transplant clinicians. As competition intensifies, intellectual property around proprietary assays, ease of integration with existing laboratory ecosystems, and the ability to demonstrate real-world clinical outcomes will determine which companies successfully capture preference among transplant centers and reference laboratories.

Actionable recommendations for diagnostics developers, laboratories, and clinical leaders to align evidence generation, interoperability, and resilient supply strategies with adoption goals

Industry leaders should prioritize evidence-generation, interoperability, and supply chain resilience to convert technological promise into routine clinical practice. First, sponsors of new diagnostics must invest in rigorous clinical validation studies and real-world evidence programs that demonstrate clinical utility across representative transplant populations and care settings. This approach accelerates clinician trust and payer engagement, while informing appropriate use guidelines. Second, vendors and laboratories should design for interoperability by adopting standardized reporting formats, APIs for electronic health records, and laboratory information system integrations that reduce implementation friction and enable scalable deployment across hospital networks.

Third, building flexible supply chains with multiple qualified suppliers, regional manufacturing contingencies, and inventory management strategies will mitigate the operational risk of external policy and logistics disruptions. Fourth, commercial strategies should emphasize value-based conversations with hospitals and payers, framing diagnostics in terms of clinical outcomes, workflow efficiency, and total cost of care. Finally, fostering collaborative pilots with transplant centers and research institutes creates an evidence-driven pathway for adoption and provides practical feedback loops that refine product design and service models.

A transparent and rigorous research methodology combining clinical literature, regulatory guidance, and frontline practitioner insights to support evidence-based conclusions

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance, public clinical guidelines, and recent industry disclosures to ensure a balanced, evidence-based perspective. Primary sources included clinical validation studies, assay performance reports, and technical white papers that describe assay methodologies and analytical characteristics. Regulatory documents and guidance statements were reviewed to capture evolving expectations for validation, reporting, and laboratory quality assurance. In addition, qualitative inputs from laboratory directors, transplant clinicians, and supply chain managers informed practical considerations around implementation, turnaround, and procurement.

Analytical rigor was maintained through cross-referencing technical claims against independent evaluations and by prioritizing data from multicenter studies and established clinical programs. Where real-world operational impacts were discussed, case examples and implementation lessons were used to illustrate common barriers and mitigation strategies. Methodological transparency is central to the report, and appendices detail inclusion criteria, source hierarchies, and limitations to support reproducibility and critical appraisal by technical audiences.

Concluding synthesis highlighting how technological maturation, operational resilience, and collaborative evidence generation will determine the clinical impact and adoption trajectory of transplant diagnostics

The convergence of advanced molecular technologies, enhanced laboratory automation, and heightened clinical expectations positions transplant diagnostics as a critical enabler of improved graft outcomes and patient safety. Throughout clinical pathways, from donor selection and HLA typing to infectious disease surveillance and graft monitoring, the adoption of higher-resolution assays and integrated data workflows is reshaping care decisions. At the same time, external pressures such as trade policy shifts and heterogeneous regional capabilities underscore the need for resilient supply chains, localized validation, and adaptable implementation strategies.

Moving forward, stakeholders who combine rigorous evidence generation, interoperable systems design, and strategic commercial engagement will be best positioned to translate diagnostic innovation into measurable clinical value. Cross-sector collaboration between assay developers, clinical centers, and informatics providers will accelerate this transition, enabling diagnostics to move from episodic testing toward continuous, data-driven monitoring that supports proactive patient management and improved long-term outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplant Diagnostics Market, by Diagnostic Application

  • 8.1. Donor Recipient Matching
  • 8.2. Graft Monitoring
  • 8.3. Hla Typing
    • 8.3.1. High Resolution
    • 8.3.2. Low Resolution
  • 8.4. Infectious Disease Screening
    • 8.4.1. Bacterial Screening
    • 8.4.2. Fungal Screening
    • 8.4.3. Viral Screening
      • 8.4.3.1. Cytomegalovirus
      • 8.4.3.2. Epstein Barr Virus
      • 8.4.3.3. Hepatitis Viruses
      • 8.4.3.4. Hiv

9. Transplant Diagnostics Market, by Technology

  • 9.1. Enzymatic Assays
  • 9.2. Flow Cytometry
  • 9.3. Pcr
    • 9.3.1. Digital Pcr
    • 9.3.2. Qpcr
  • 9.4. Sequencing
    • 9.4.1. Next Generation
    • 9.4.2. Sanger

10. Transplant Diagnostics Market, by Organ Type

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Transplant Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
  • 11.4. Transplant Centers

12. Transplant Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transplant Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transplant Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transplant Diagnostics Market

16. China Transplant Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Adaptive Biotechnologies Corporation
  • 17.7. altona Diagnostics GmbH
  • 17.8. Arquer Diagnostics Ltd.
  • 17.9. BAG Group
  • 17.10. Becton, Dickinson and Company
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Biogenuix Medsystems Pvt. Ltd
  • 17.13. BioMerieux SA
  • 17.14. Bruker Corporation
  • 17.15. Caredx Inc.
  • 17.16. CareDx, Inc.
  • 17.17. CLONIT srl
  • 17.18. Diagnostica Longwood SL
  • 17.19. DiaSorin S.p.A.
  • 17.20. Eurofins Scientific SE
  • 17.21. F. Hoffmann-La Roche Ltd.
  • 17.22. Genome Diagnostics B.V.
  • 17.23. Hologic, Inc.
  • 17.24. Illumina, Inc
  • 17.25. Immucor, Inc.
  • 17.26. Laboratory Corporation of America Holdings
  • 17.27. Luminex Corporation
  • 17.28. Merck KGaA
  • 17.29. NanoString Technologies, Inc.
  • 17.30. Novartis AG
  • 17.31. PathoNostics B.V
  • 17.32. QIAGEN, N.V.
  • 17.33. Quest Diagnostics Incorporated
  • 17.34. Randox Laboratories Ltd.
  • 17.35. Takara Bio Inc.
  • 17.36. Thermo Fisher Scientific Inc.
  • 17.37. TransMedics, Inc.
  • 17.38. Zimmer Biomet Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 212. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 214. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 216. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 217. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 245. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 246. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 249. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 250. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 256. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 257. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 258. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 260. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)